Brand Intelligence Graph
Company Overview
About Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable of making all 12 possible base-pair changes, small insertions, and deletions in DNA without double-strand breaks. The company has $191 million in cash runway into 2027, INDs planned for Wilson's Disease and Alpha-1 antitrypsin deficiency (AATD) in 2026, and a $55 million upfront collaboration with Bristol Myers Squibb worth up to $3.5 billion in milestones.
Business Model & Competitive Advantage
Prime editing is "find and replace" for genetic code: unlike CRISPR-Cas9 (which cuts DNA and relies on error-prone repair mechanisms), Prime editing makes precise targeted changes using a reverse transcriptase that writes new genetic sequences at the target site. This precision enables correction of point mutations — the genetic basis of thousands of rare diseases — without the unintended insertions and deletions that CRISPR cutting produces.
Competitive Landscape 2025–2026
The Phase 1 CGD (Chronic Granulomatous Disease) data presented by Prime Medicine represents the first human clinical validation of Prime editing: rapid restoration of NADPH oxidase function after a single ex vivo infusion in CGD patients demonstrates the technology works in human cells and achieves meaningful therapeutic correction. This data de-risks all of Prime's subsequent programs targeting rare genetic liver and blood diseases.
Key Differentiators
Strong Challenger
Prime Medicine is an established challenger with significant market presence and competitive offerings in BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare Prime Medicine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Prime Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Prime Medicine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Prime Medicine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →